The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article metrics

Ovarian Cancer

The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

Online download statistics by month:

Online download statistics by month: February 2019 to March 2023

	Abstract	Full	Pdf
Feb 2019	10	0	0
Mar 2019	34	0	1
Apr 2019	49	0	2
May 2019	48	0	3
Jun 2019	24	0	2
Jul 2019	22	0	1
Aug 2019	40	0	1
Sep 2019	32	0	0
Oct 2019	26	0	0
Nov 2019	34	0	2
Dec 2019	26	0	0
Jan 2020	53	0	1
Feb 2020	38	0	0
Mar 2020	6	0	2
Apr 2020	56	0	3
May 2020	44	0	1
Jun 2020	116	0	1
Jul 2020	47	0	1
Aug 2020	20	0	1
Sep 2020	23	0	0
Oct 2020	33	0	0
Nov 2020	22	0	0
Dec 2020	29	0	0
Jan 2021	35	0	0
Feb 2021	11	0	0
Mar 2021	28	0	1
Apr 2021	64	0	1
May 2021	12	0	1
Jun 2021	1	0	0
Jul 2021	1	0	0
Aug 2021	1	0	0
Oct 2021	8	0	0
Nov 2021	6	0	1
Dec 2021	26	0	1
Jan 2022	24	0	0
Feb 2022	20	0	0
Mar 2022	27	0	3
Apr 2022	19	0	0
May 2022	46	0	1
Jun 2022	59	0	1
Jul 2022	59	0	0
Aug 2022	60	0	0
Sep 2022	58	0	0
Oct 2022	44	0	0
Nov 2022	25	0	0
Dec 2022	37	0	1
Jan 2023	23	0	0
Feb 2023	84	0	1
Mar 2023	46	0	0
Total	1656	0	34